Precision BioSciences presents preclinical data from PBGENE-DMD program
Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...
Hosted on MSN1mon
Precision BioSciences announces board member's retirement
Precision BioSciences Inc . (NASDAQ:DTIL), a profitable gene editing company with a market capitalization of $38.7 million, has announced the retirement of Dr. Sam Wadsworth from its Board of ...
Business Wire26d
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...